Study of an Electronic Clinical Decision Support Tool for Treating Lower Respiratory Tract Infection
in Hospitals in Southern Sri Lanka
A Stepped-Wedge Cluster Randomized Trial
Led by Duke University · Updated on 2026-07-23
765
Participants Needed
3
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an electronic clinical decision support tool eCDST designed to help diagnose and treat lower respiratory tract infections LRTI in patients aged 14 years and older at three hospitals in Southern Sri Lanka. This open-label, stepped-wedge, cluster-randomized trial aims to compare clinical outcomes and antibacterial prescribing between patients managed with the eCDST and those receiving usual care. The study will enroll 765 patients and monitor them over 30 days to assess the impact of the tool on treatment decisions and patient health.
Participants are grouped by hospital wards that switch from usual care to the eCDST at intervals of 3 to 6 months until all wards use the intervention. Clinicians in the intervention arm use the eCDST on mobile phones to receive diagnostic plans and treatment recommendations, including point-of-care testing conducted by clinical or trained research staff. Usual care participants receive standard diagnostic testing and treatment at clinician discretion. Final decisions on antimicrobial prescriptions remain with the treating doctors.
During the study, participants are followed for 30 days after enrollment to record clinical outcomes and antibacterial use, with a maximum antibacterial prescription duration of 14 days. Researchers will monitor various outcomes including adverse events related to withholding antibacterials, duration of antibacterial use, hospital readmissions, ventilator use, ICU admissions, oxygen supplementation, and physician adherence to eCDST recommendations. Assessments include clinical monitoring and routine diagnostic tests according to each treatment arm.
CONDITIONS
Brief Title
TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): a Stepped-Wedge Cluster Randomized Trial
Research Team
G
Gayani Tillekeratne, MD, MSc
S
Stefany Olague, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
Who Can Participate
Age: 14Years +
All Genders
Eligibility Criteria
You may qualify if you...
Admitted to hospital within the prior 48 hours
Evidence of new acute respiratory illness (less than 14 days of symptoms), such as new cough, sputum production, chest pain, or rapid breathing
Evidence of acute infection including fever, chills, low body temperature, abnormal white blood cell counts, or new altered mental status
Ability and willingness to provide informed consent (patient, parent, or legally authorized representative)
Children aged 14-17 years able to provide assent
Ability to complete a 30-day follow-up visit in person or by telephone
You will not qualify if you...
Hospitalized within the last 28 days
Previously enrolled in this clinical trial
Surgery within the past 7 days
Unable or unwilling to complete the 30-day follow-up
Likely to be transferred from medical wards within 24 hours of enrollment
Conditions requiring unlikely withholding of antibacterials, including vasopressor therapy, cystic fibrosis, severe immunosuppression, non-respiratory infection, lung abscess or empyema, or respiratory failure requiring ventilation at enrollment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 14 days during hospitalization
Participants receive either usual care or care guided by the electronic clinical decision support tool (eCDST) during their hospital stay. Clinicians use the tool to assist diagnosis and treatment decisions, including point-of-care testing as recommended.
Follow-up
Duration - 30 days
Participants are followed for 30 days after enrollment to record clinical outcomes and any antimicrobial use. Follow-up may be in person or by telephone.
1 follow-up visit or telephone call
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Assessing Lung Ultrasound to Guide Antibiotic Use in Hospitalized Children and Teens with Lung Infections
Study of an Electronic Clinical Decision Support Tool for Treating Lower Respiratory Tract Infection
in Hospitals in Southern Sri Lanka
A Stepped-Wedge Cluster Randomized Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): study protocol for a stepped-wedge, cluster-randomized clinical trial.